Chinese pharmaceutical company Akeso is being celebrated for its groundbreaking success in the global biotech arena, drawing comparisons to the momentous rise of Chinese AI startup DeepSeek. Akeso’s innovative cancer immunotherapy drug, ivonescimab, has achieved promising results in clinical trials, significantly outpacing Western competitors in the fight against non-small cell lung cancer.
In the latest phase 3 clinical trial results, published in The Lancet last week, ivonescimab showed that half of its patients were able to go 11.1 months without their condition worsening, a metric known as median progression-free survival (PFS). By comparison, pembrolizumab, the world’s leading cancer drug from US pharmaceutical giant Merck (sold as Keytruda), recorded a PFS of just 5.8 months.
This impressive performance has drawn significant attention to Akeso, especially in the context of the ongoing US-China tech war, where biotechnology has emerged as a crucial front. Akeso’s success highlights China’s growing capability in the global pharmaceutical industry, traditionally dominated by Western giants.
The significance of this breakthrough was underscored when a member of the Chinese People’s Political Consultative Conference recently brought ivonescimab to the spotlight during the “two sessions” in Beijing. This development has sparked excitement across China, with media outlets referring to it as the Chinese biotech industry’s “DeepSeek moment.”
The term is a nod to DeepSeek’s recent success in the AI sector, where it developed cutting-edge AI models at a fraction of the cost of its global competitors. Just as DeepSeek’s achievement shook the tech world, Akeso’s success in the highly competitive field of cancer treatment is being seen as a testament to China’s resilience and innovation, especially in the face of stringent US restrictions on technology and intellectual property.
As Akeso’s ivonescimab moves closer to regulatory approval, it is poised to challenge the dominance of Western drugs like Keytruda, signaling a new era of competition in the biotech sector. With this breakthrough, China is positioning itself as a major player in global healthcare, setting the stage for a new chapter in the ongoing US-China rivalry.
